We're proud to begin a new chapter in our life-saving work. We are NMDP BioTherapies. As a global leader in cell therapy, we believe each of us holds the key to curing blood cancers and disorders. Our organization has decades of life-saving work as the most diverse blood stem cell donor registry and as leading research and health care partners. Today, by uniting and simplifying our names, we show the breadth and depth of our abilities to advance cell therapy. Although our name has changed, our commitment to ensuring every patient can receive their life-saving therapy remains. NMDP. Find cures. Save lives. Discover more about our new unified identity ???https://bit.ly/3HvgSdn #NMDP #CellTherapy #SavingLives
NMDP BioTherapies
生物技术研究
Minneapolis，Minnesota 7,107 位关注者
Empowering the discovery, development and delivery of next-generation therapies.
关于我们
Introducing NMDP BioTherapies, formerly known as Be The Match BioTherapies. Our name has changed but our mission has not: We save lives through cell therapy. At NMDP, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives. Learn more about our career opportunities at nmdp.org/careers.
- 网站
-
https://nmdpbiotherapies.com/
NMDP BioTherapies的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Minneapolis，Minnesota
- 类型
- 非营利机构
- 领域
- cell sourcing、cell therapy clinical trial network、collection network development、cell therapy logistics、supply chain case management、cell therapy supply chain、quality system audit、collection site qualification、cell therapy patient outcomes、cell therapy starting material、bioinformatics、cell therapy transport、cell therapy delivery、consented cell donors、cryopreserved cells、apheresis starting material、clinical trial design、cell therapy clinical research和cell therapy source material
地点
-
主要
获取路线
500 N 5th St
US，Minnesota，Minneapolis，55401
NMDP BioTherapies员工
-
Tom Hochuli
President | Chief Executive Officer (CEO) | Board Advisor | Cell and Gene Therapy (CGT) | CDMO | Private Equity | Startup | Healthcare |…
-
Renee O.
Director, Sales and Business Development, Cell and Gene Therapy, at NMDP BioTherapies
-
Allison McShane, MPH
Principal Solution Owner: developing solutions for cell & gene therapies at NMDP BioTherapies
-
Tommie Gamble
Sales & Business Development Manager @ NMDP BioTherapies
动态
-
Happening now! We’re thrilled to be in Boston at the 6th annual Supply Chain & Logistics for Cell & Gene Therapies Summit. Be sure to catch Jeni Newman's talk on building strong partnerships to optimize supply chain success. Get in touch with our team here https://lnkd.in/g9nm4n5R
-
-
We’ll be in Boston next week at the 6th annual Supply Chain & Logistics for Cell & Gene Therapies Summit! Jeni Newman will be giving a talk titled “Optimizing Supply Chain Success: Building Strong Partnerships,” on March 13th at 9:00 AM ET. To get in touch with our team, click below. https://lnkd.in/g9nm4n5R
-
-
We’re in tropical Honolulu for this year’s Tandem Meetings. Molly Mjolsness, MBA, PMP and Joy Aho are representing the NMDP BioTherapies family, and would love to connect with you! Join us at booth #335 or contact us at https://lnkd.in/g9nm4n5R #TANDEM25
-
-
Join us at the 2025 Tandem Transplantation & Cellular Therapy Meetings of ASTCT? CIBMTR? next week! To get in touch with our team, click below. https://lnkd.in/g9nm4n5R #TANDEM25
-
-
It’s here! We’re thrilled to be in Dallas at this year’s Advanced Therapies Week. Three members of our team: Renee O., Erin King, and Anne Dircks are representing NMDP BioTherapies, and would love to chat with you! Get in touch below. https://lnkd.in/g9nm4n5R #ATW
-
-
We can’t wait to connect with you at the 2025 Advanced Therapies Week in Dallas next week! Stop by our meeting room #D170 or get in touch with our team: https://lnkd.in/g9nm4n5R #ATW #NMDPBiotherapies #CellTherapy
-
-
Regulatory Scientist | Cell & Gene Therapies | Process & Analytical Development | CMC | Immunology | Infectious Diseases | Biomarkers
Major FDA CBER Update: Six New Guidance Documents for HCT/P Establishments published 06JAN2025 It’s been a while since my last post, but I have an important update for my colleagues in the cell therapy industry (and adjacent ecosystems). Earlier today, the FDA's CBER dropped six new guidance documents for HCT/P establishments to kick off the 2025 regulatory season. One of them is a long-awaited draft guidance on donor eligibility determinations—an update that hasn’t been revisited since 2007! Here’s a quick rundown: (Draft) Donor Eligibility Determination https://lnkd.in/gYKRHFiG (Draft) HIV-Specific Recommendations https://lnkd.in/g_xkgHA2 (Draft) HCV-Specific Recommendations https://lnkd.in/gjedYg9C (Draft) HBV-Specific Recommendations https://lnkd.in/gcMdEd6G (Final) Mycobacterium tuberculosis (Mtb) Recommendations - Effective today; Enforced as of 03Feb2025 - Formally designates Mtb as a Relevant Communicable Disease Agent or Disease (RCDAD) https://lnkd.in/gB6UjTk5 (Final) Sepsis Recommendations -Effective today; Enforced as of 03FEB2025 https://lnkd.in/guvWQUKE Altogether, these new and updated guidances total over 140 pages of regulatory reading. I’m gearing up to dive in and will share my takeaways as I go (so much for clearing my January backlog). Stay tuned! Why it matters: - Compliance Deadline: HCT/P establishments have until 03FEB2025 to comply with the final Mtb and Sepsis guidances. - Industry Impact: Adding Mtb to the RCDAD list directly affects donor eligibility determinations under 21 CFR 1271.3(r)(2). A big thank-you to the FDA staff and collaborating SMEs who put in the time and effort to develop these guidances. And to my fellow quality and regulatory professionals: buckle up, because the next few weeks (and months) will be busy! What are your thoughts on these updates? Let me know in the comments below! #CellTherapy #InfectiousDiseases #GoodTissuePractices #RegulatoryAffairs #RegulatoryCompliance #Donors #Allogeneic #celltherapymanufacturing #transplant #HSC #stemcells #CARTcells #startingmaterials #eligibility
-
Thank you Mantell Associates for giving a shoutout to our very own Tom Hochuli! We’re proud to be led by someone with such a deep understanding of the cell and gene therapy landscape, along with a passion for improving next-generation therapies to help more patients.
Our latest 'Spotlight' features Tom Hochuli, President and Board Member at NMDP BioTherapies! Tom is an experienced Senior Executive with a demonstrated history of results, working in the pharmaceutical, medical device, biologics and consumer goods industries. In his role at NMDP BioTherapies, he will lead the organization into it's promising future phase, which as always is mission-driven and patient-first. #leadership #clevel #cellandgenetherapy
-
-
Five members of the NMDP BioTherapies team will be in sunny San Diego for the 66th ASH Annual Meeting and Exposition this weekend! To learn more about our solutions that accelerate cell and gene therapy development, visit us at Booth 112. We’d love to see you there! #ASH24 #CellTherapy #NMDPBioTherapies
-